{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:44:48Z","timestamp":1790203488042,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:00:00Z","timestamp":1565654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R35HL 144980"],"award-info":[{"award-number":["R35HL 144980"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"DOI":"10.3389\/fphys.2019.00992","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T10:38:51Z","timestamp":1565692731000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload"],"prefix":"10.3389","volume":"10","author":[{"given":"Hyun Seok","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo P.","family":"Baldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Pindado","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Faggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn C.","family":"Knollmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1161\/CIRCRESAHA.116.305347","article-title":"The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.","volume":"116","author":"Bannister","year":"2015","journal-title":"Circ. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1073\/pnas.1816685116","article-title":"Unnatural verticilide enantiomer inhibits type 2 ryanodine receptor-mediated calcium leak and is antiarrhythmic.","volume":"116","author":"Batiste","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B3","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/europace\/euq279","article-title":"Efficacy of flecainide in a patient with catecholaminergic polymorphic ventricular tachycardia.","volume":"13","author":"Biernacka","year":"2011","journal-title":"Europace"},{"key":"B4","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1161\/01.RES.0000169067.51055.72","article-title":"Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor.","volume":"96","author":"Cerrone","year":"2005","journal-title":"Circ. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"7636","DOI":"10.1073\/pnas.0902919106","article-title":"Ablation of triadin causes loss of cardiac Ca2+ release units, impaired excitation-contraction coupling, and cardiac arrhythmias.","volume":"106","author":"Chopra","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B6","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1161\/CIRCULATIONAHA.112.001216","article-title":"Calmodulin mutations associated with recurrent cardiac arrest in infants.","volume":"127","author":"Crotti","year":"2013","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"H1250","DOI":"10.1152\/ajpheart.00779.2011","article-title":"Calsequestrin 2 and arrhythmias.","volume":"302","author":"Faggioni","year":"2012","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00246-012-0256-1","article-title":"Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia.","volume":"33","author":"Faggioni","year":"2012","journal-title":"Pediatr. Cardiol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.yjmcc.2011.07.002","article-title":"Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin.","volume":"51","author":"Galimberti","year":"2011","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.116.004161","article-title":"Novel CPVT-associated calmodulin mutation in CALM3 (CALM3-A103V) activates arrhythmogenic Ca waves and sparks.","volume":"9","author":"Gomez-Hurtado","year":"2016","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.yjmcc.2009.10.005","article-title":"Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.","volume":"48","author":"Hilliard","year":"2010","journal-title":"J. mol. cell. cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/j.1540-8159.2012.03421.x","article-title":"Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia.","volume":"35","author":"Hong","year":"2012","journal-title":"Pacing clin. Electrophysiol."},{"key":"B13","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1056\/NEJMra000650","article-title":"Sudden death due to cardiac arrhythmias.","volume":"345","author":"Huikuri","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1161\/CIRCEP.110.959916","article-title":"Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.","volume":"4","author":"Hwang","year":"2011","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1161\/CIRCRESAHA.114.303391","article-title":"Divergent regulation of ryanodine receptor 2 calcium release channels by arrhythmogenic human calmodulin missense mutants.","volume":"114","author":"Hwang","year":"2014","journal-title":"Circ. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jelectrocard.2012.05.002","article-title":"Effects of flecainide therapy on inappropriate shocks and arrhythmias in catecholaminergic polymorphic ventricular tachycardia.","volume":"45","author":"Jacquemart","year":"2012","journal-title":"J. Electrocardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1001\/jamacardio.2017.1320","article-title":"Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial.","volume":"2","author":"Kannankeril","year":"2017","journal-title":"JAMA Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.hrthm.2010.07.004","article-title":"Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice.","volume":"7","author":"Katz","year":"2010","journal-title":"Heart Rhythm"},{"key":"B19","first-page":"2510","article-title":"Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia.","volume":"116","author":"Knollmann","year":"2006","journal-title":"J. Clin. Invest."},{"key":"B20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1161\/01.RES.0000059562.91384.1A","article-title":"Familial hypertrophic cardiomyopathy-linked mutant troponin T causes stress-induced ventricular tachycardia and Ca2+-dependent action potential remodeling.","volume":"92","author":"Knollmann","year":"2003","journal-title":"Circ. Res."},{"key":"B21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1469-7793.2000.t01-1-00483.x","article-title":"Remodelling of ionic currents in hypertrophied and failing hearts of transgenic mice overexpressing calsequestrin.","author":"Knollmann","year":"2000","journal-title":"J. Physiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1042\/BJ20080489","article-title":"Caffeine induces Ca2+ release by reducing the threshold for luminal Ca2+ activation of the ryanodine receptor.","volume":"414","author":"Kong","year":"2008","journal-title":"Biochem. J."},{"key":"B23","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1161\/01.CIR.103.23.2822","article-title":"Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21.","volume":"103","author":"Lahat","year":"2001","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/01.CIR.91.5.1512","article-title":"Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients.","volume":"91","author":"Leenhardt","year":"1995","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1161\/01.RES.0000235869.50747.e1","article-title":"Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model.","volume":"99","author":"Liu","year":"2006","journal-title":"Circ. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1161\/CIRCRESAHA.111.247338","article-title":"Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.","volume":"109","author":"Liu","year":"2011","journal-title":"Circ. Res."},{"key":"B27","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1113\/jphysiol.2009.172155","article-title":"Store overload-induced Ca2+ release as a triggering mechanism for CPVT and MH episodes caused by mutations in RYR and CASQ genes.","volume":"587","author":"MacLennan","year":"2009","journal-title":"J. Physiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.ajhg.2012.08.015","article-title":"Mutations in calmodulin cause ventricular tachycardia and sudden cardiac death.","volume":"91","author":"Nyegaard","year":"2012","journal-title":"Am. J. Hum. Genet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.hlc.2011.10.008","article-title":"Guidelines for the diagnosis and management of catecholaminergic polymorphic ventricular tachycardia.","volume":"21","author":"Pflaumer","year":"2012","journal-title":"Heart Lung Circ."},{"key":"B30","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/europace\/euq517","article-title":"Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.","volume":"13","author":"Pott","year":"2011","journal-title":"Europace"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131179","article-title":"channel activity of cardiac ryanodine receptors (ryr2) determines potency and efficacy of flecainide and R-Propafenone against arrhythmogenic calcium waves in ventricular cardiomyocytes.","volume":"10","author":"Savio-Galimberti","year":"2015","journal-title":"PLoS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/cvr\/cvt012","article-title":"Flecainide reduces Ca(2+) spark and wave frequency via inhibition of the sarcolemmal sodium current.","volume":"98","author":"Sikkel","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1016\/j.jacc.2011.01.026","article-title":"Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.","volume":"57","author":"van der Werf","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nm.1942","article-title":"Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.","volume":"15","author":"Watanabe","year":"2009","journal-title":"Nat. Med."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphys.2019.00992\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T07:39:51Z","timestamp":1569224391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphys.2019.00992\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,13]]},"references-count":34,"alternative-id":["10.3389\/fphys.2019.00992"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2019.00992","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,13]]},"article-number":"992"}}